

Tacrosolv



Novel ultra-low dose, preservative-free Tacrolimus eye drops targeting ocular inflammation

Tacrosolv is a fully dissolved clear solution of Tacrolimus based on the Marinosolv® technology. Due to its anti-inflammatory and immunomodulatory effect, Tacrosolv offers great potential as treatment in different inflammatory diseases of the ocular surface.



Benefits

- Solution instead of suspension – significant decrease of applied dose, faster onset of action & better side effect profile
- Preservative-free formulation possible
- Clinically validated in phase IIa trial

Potential to treat a multitude of ophthalmic inflammatory eye diseases

Clinical phase IIa data¹

Anti-inflammatory activity in model indication allergic conjunctivitis: 64 patients exposed to allergen-challenge once were treated with 0.005% solubilized Tacrolimus (two drops (50µl) per day for 8 days)



*TOSS: total ocular symptom score: ocular itching, watery eyes, ocular redness, gritty feeling


Significant reduction of ocular symptoms after one week of treatment – dose reduced by 95% compared to product marketed in Asia

¹Sladek, S. et al., medRxiv 2024.04.30.24306626; doi: <https://doi.org/10.1101/2024.04.30.24306626>

²Baseline corrected

Marinosolv® technology

- Significantly increases bioavailability: Allows dose reduction & faster onset of action
- Reduces pharmaceutical compounds in wastewater
- Clinically validated & patent protected
- Suitable for sensitive tissues such as eyes and nose



Partnering opportunities

- Classical license deal with downpayment, milestones and royalties
- Patent protected until 2036
- Suitable for different ophthalmic indications:
 - Moderate to severe dry eye
 - Severe allergic keratoconjunctivitis
 - Vernal keratoconjunctivitis
 - Graft vs. host disease
 - Herpetic stromal keratitis
 - Corneal transplantation
 - Autoimmune diseases

„It is quite unheard of to have a signal of efficacy in just 8 days.“
Expert at Wilmer Eye Institute, USA

„Tacrosolv could be a breakthrough.“
Expert at Tufts University, Boston

„You don't have to convince me that Tacrolimus works.“
Expert at Institut de la Vision, France

Key opinion leaders confirm high unmet medical need for fully solubilized Tacrolimus

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with globally marketed therapeutics and a growing development pipeline. The Company focuses on the development of innovative products based on two patent-protected technology platforms, Marinosolv® and Carragelose®. Marinomed is listed on the Vienna Stock Exchange (VSE: MARI).



For more information, please contact our Business Development team:
E-Mail: bd@marinomed.com
Tel.: +43 2262 90300
www.marinomed.com

Follow us on



Tacrosolv



Marinomed Biotech AG, www.marinomed.com
Hovengasse 25, 2100 Korneuburg, Austria